Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake.
Identifieur interne : 003845 ( Main/Exploration ); précédent : 003844; suivant : 003846Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake.
Auteurs : RBID : pubmed:11168306English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), Adolescent, Adrenergic Fibers (physiology), Adult, Aged, Antibiotics, Antineoplastic (adverse effects), Antibodies, Monoclonal (diagnostic use), Cardiomyopathies (chemically induced), Cardiomyopathies (pathology), Cardiomyopathies (radionuclide imaging), Fatty Acids (pharmacokinetics), Female, Heart (innervation), Heart Failure (chemically induced), Heart Failure (pathology), Heart Failure (radionuclide imaging), Humans, Male, Middle Aged, Muscle Fibers, Skeletal (pathology), Myocardium (metabolism), Myocardium (pathology), Organometallic Compounds (diagnostic use), Radiopharmaceuticals (diagnostic use), Stroke Volume, Tomography, Emission-Computed, Single-Photon, Ventricular Function, Left.
- MESH :
- chemical , adverse effects : Antibiotics, Antineoplastic.
- chemical , diagnostic use : 3-Iodobenzylguanidine, Antibodies, Monoclonal, Organometallic Compounds, Radiopharmaceuticals.
- chemically induced : Cardiomyopathies, Heart Failure.
- innervation : Heart.
- metabolism : Myocardium.
- pathology : Cardiomyopathies, Heart Failure, Muscle Fibers, Skeletal, Myocardium.
- chemical , pharmacokinetics : Fatty Acids.
- physiology : Adrenergic Fibers.
- radionuclide imaging : Cardiomyopathies, Heart Failure.
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Stroke Volume, Tomography, Emission-Computed, Single-Photon, Ventricular Function, Left.
Abstract
Cardiotoxicity of anthracyclines is a clinical challenge in cancer chemotherapy. Limited data is available on the physiological mechanisms responsible for anthracycline-induced heart failure or its recovery. We studied four patients with a history of severe anthracycline-induced heart failure manifested 2-116 months earlier by using radionuclide ventriculography for the measurement of left ventricular function, indium-111-antimyosin scintigraphy for the detection of myocardial cell injury and iodine-123-metaiodobenzylguanidine (MIBG) scintigraphy for the assessment of cardiac adrenergic innervation. Myocardial perfusion and fatty acid utilization were assessed with iodine-123-paraphenyl pentadecanoid acid (pPPA) and single photon emission computed tomography (SPECT). Symptoms of congestive heart failure (CHF) were still present in two patients whereas the others were asymptomatic at the time of the study. The patients who showed complete clinical recovery had normal or near normal left ventricular ejection fraction (LVEF) (47 and 52%), whereas the patients with symptoms of heart failure had low ejection fractions (21 and 31%). All patients presented with abnormal antimyosin uptake and decreased myocardial MIBG uptake. Patients with low ejection fraction tended to have higher antimyosin uptake suggesting more severe, persistent myocyte injury. All but one patient showed normal fatty acid utilization. These data suggest that patients with a history of severe anthracycline-induced cardiomyopathy have persistent myocardial cell injury and adrenergic dysfunction up to 10 years after the development of heart failure. These findings seem to be present regardless of recovery of left ventricular function.
PubMed: 11168306
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake.</title><author><name sortKey="Nousiainen, T" uniqKey="Nousiainen T">T Nousiainen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Kuopio University Hospital, 70211 Kuopio, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Medicine, Kuopio University Hospital, 70211 Kuopio</wicri:regionArea></affiliation></author><author><name sortKey="Vanninen, E" uniqKey="Vanninen E">E Vanninen</name></author><author><name sortKey="Jantunen, E" uniqKey="Jantunen E">E Jantunen</name></author><author><name sortKey="Remes, J" uniqKey="Remes J">J Remes</name></author><author><name sortKey="Kuikka, J" uniqKey="Kuikka J">J Kuikka</name></author><author><name sortKey="Hartikainen, J" uniqKey="Hartikainen J">J Hartikainen</name></author></titleStmt><publicationStmt><date when="2001">2001</date><idno type="RBID">pubmed:11168306</idno><idno type="pmid">11168306</idno><idno type="wicri:Area/Main/Corpus">003B11</idno><idno type="wicri:Area/Main/Curation">003B11</idno><idno type="wicri:Area/Main/Exploration">003845</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>Adolescent</term><term>Adrenergic Fibers (physiology)</term><term>Adult</term><term>Aged</term><term>Antibiotics, Antineoplastic (adverse effects)</term><term>Antibodies, Monoclonal (diagnostic use)</term><term>Cardiomyopathies (chemically induced)</term><term>Cardiomyopathies (pathology)</term><term>Cardiomyopathies (radionuclide imaging)</term><term>Fatty Acids (pharmacokinetics)</term><term>Female</term><term>Heart (innervation)</term><term>Heart Failure (chemically induced)</term><term>Heart Failure (pathology)</term><term>Heart Failure (radionuclide imaging)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Muscle Fibers, Skeletal (pathology)</term><term>Myocardium (metabolism)</term><term>Myocardium (pathology)</term><term>Organometallic Compounds (diagnostic use)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Stroke Volume</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Ventricular Function, Left</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibiotics, Antineoplastic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Antibodies, Monoclonal</term><term>Organometallic Compounds</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cardiomyopathies</term><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="innervation" xml:lang="en"><term>Heart</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Myocardium</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cardiomyopathies</term><term>Heart Failure</term><term>Muscle Fibers, Skeletal</term><term>Myocardium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Fatty Acids</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Adrenergic Fibers</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Cardiomyopathies</term><term>Heart Failure</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Stroke Volume</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Ventricular Function, Left</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cardiotoxicity of anthracyclines is a clinical challenge in cancer chemotherapy. Limited data is available on the physiological mechanisms responsible for anthracycline-induced heart failure or its recovery. We studied four patients with a history of severe anthracycline-induced heart failure manifested 2-116 months earlier by using radionuclide ventriculography for the measurement of left ventricular function, indium-111-antimyosin scintigraphy for the detection of myocardial cell injury and iodine-123-metaiodobenzylguanidine (MIBG) scintigraphy for the assessment of cardiac adrenergic innervation. Myocardial perfusion and fatty acid utilization were assessed with iodine-123-paraphenyl pentadecanoid acid (pPPA) and single photon emission computed tomography (SPECT). Symptoms of congestive heart failure (CHF) were still present in two patients whereas the others were asymptomatic at the time of the study. The patients who showed complete clinical recovery had normal or near normal left ventricular ejection fraction (LVEF) (47 and 52%), whereas the patients with symptoms of heart failure had low ejection fractions (21 and 31%). All patients presented with abnormal antimyosin uptake and decreased myocardial MIBG uptake. Patients with low ejection fraction tended to have higher antimyosin uptake suggesting more severe, persistent myocyte injury. All but one patient showed normal fatty acid utilization. These data suggest that patients with a history of severe anthracycline-induced cardiomyopathy have persistent myocardial cell injury and adrenergic dysfunction up to 10 years after the development of heart failure. These findings seem to be present regardless of recovery of left ventricular function.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11168306</PMID><DateCreated><Year>2001</Year><Month>02</Month><Day>22</Day></DateCreated><DateCompleted><Year>2001</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0144-5979</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical physiology (Oxford, England)</Title><ISOAbbreviation>Clin Physiol</ISOAbbreviation></Journal><ArticleTitle>Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake.</ArticleTitle><Pagination><MedlinePgn>123-8</MedlinePgn></Pagination><Abstract><AbstractText>Cardiotoxicity of anthracyclines is a clinical challenge in cancer chemotherapy. Limited data is available on the physiological mechanisms responsible for anthracycline-induced heart failure or its recovery. We studied four patients with a history of severe anthracycline-induced heart failure manifested 2-116 months earlier by using radionuclide ventriculography for the measurement of left ventricular function, indium-111-antimyosin scintigraphy for the detection of myocardial cell injury and iodine-123-metaiodobenzylguanidine (MIBG) scintigraphy for the assessment of cardiac adrenergic innervation. Myocardial perfusion and fatty acid utilization were assessed with iodine-123-paraphenyl pentadecanoid acid (pPPA) and single photon emission computed tomography (SPECT). Symptoms of congestive heart failure (CHF) were still present in two patients whereas the others were asymptomatic at the time of the study. The patients who showed complete clinical recovery had normal or near normal left ventricular ejection fraction (LVEF) (47 and 52%), whereas the patients with symptoms of heart failure had low ejection fractions (21 and 31%). All patients presented with abnormal antimyosin uptake and decreased myocardial MIBG uptake. Patients with low ejection fraction tended to have higher antimyosin uptake suggesting more severe, persistent myocyte injury. All but one patient showed normal fatty acid utilization. These data suggest that patients with a history of severe anthracycline-induced cardiomyopathy have persistent myocardial cell injury and adrenergic dysfunction up to 10 years after the development of heart failure. These findings seem to be present regardless of recovery of left ventricular function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nousiainen</LastName><ForeName>T</ForeName><Initials>T</Initials><Affiliation>Department of Medicine, Kuopio University Hospital, 70211 Kuopio, Finland.</Affiliation></Author><Author ValidYN="Y"><LastName>Vanninen</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jantunen</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Remes</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kuikka</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hartikainen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Physiol</MedlineTA><NlmUniqueID>8309768</NlmUniqueID><ISSNLinking>0144-5979</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibiotics, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Fatty Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Organometallic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>138660-99-8</RegistryNumber><NameOfSubstance>imciromab pentetate</NameOfSubstance></Chemical><Chemical><RegistryNumber>35MRW7B4AD</RegistryNumber><NameOfSubstance>3-Iodobenzylguanidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">3-Iodobenzylguanidine</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Adrenergic Fibers</DescriptorName><QualifierName MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName><QualifierName MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cardiomyopathies</DescriptorName><QualifierName MajorTopicYN="Y">chemically induced</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fatty Acids</DescriptorName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Heart</DescriptorName><QualifierName MajorTopicYN="N">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName MajorTopicYN="N">chemically induced</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Myocardium</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Organometallic Compounds</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>13</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>13</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11168306</ArticleId><ArticleId IdType="pii">cph292</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003845 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003845 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11168306
|texte= Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11168306" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |